Phaseline

Companies › PeptiDream

PeptiDream: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PD-32766D (Copper-64 [64Cu] labeled peptide)
64Cu-labeled peptide targeting carbonic anhydrase IX (CA9) for PET/CT imaging
CA9Phase 1Clear Cell Renal Cell CarcinomaMay 2029
PD-32766T (Actinium-225 [225Ac] labeled peptide)
225Ac-labeled peptide targeting carbonic anhydrase IX (CA9) for targeted alpha particle th
CA9Phase 1Clear Cell Renal Cell CarcinomaMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07688187PD-32766D (Copper-64 [64Cu] labeled peptide)Phase 1Clear Cell Renal Cell CarcinomaOncologyMay 2029
NCT07688187PD-32766T (Actinium-225 [225Ac] labeled peptide)Phase 1Clear Cell Renal Cell CarcinomaOncologyMay 2029

Targets

CA9 (2)

Companies with the same targets

Telix Pharmaceuticals (Innovations) Beijing Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.